Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis
Resumen: Background: We aimed to investigate the state of cardiovascular risk/protection factors in early psychosis patients.
Methods: A total 119 subjects were recruited during the first year after their first episode of psychosis. Eighty-five of these subjects were followed during the next 6 months. Cardiovascular risk/protection factors were measured in plasma and co-variated by sociodemographic/clinical characteristics. Multiple linear regression models detected the change of each biological marker from baseline to follow-up in relation to clinical scales, antipsychotic medication, and pro-/antiinflammatory mediators.
Results: Glycosylated hemoglobin is a state biomarker in first episode of psychosis follow-up patients and inversely correlated to the Global Assessment of Functioning scale. We found opposite alterations in the levels of VCAM-1 and E-selectin in first episode of psychosis baseline conditions compared with control that were absent in the first episode of psychosis follow-up group. Adiponectin levels decreased in a continuum in both pathological time points studied. E-Selectin plasma levels were inversely related to total antipsychotic equivalents and adiponectin levels inversely co-related to the Global Assessment of Functioning scale. Finally, adiponectin levels were directly related to antiinflammatory nuclear receptor PPARy expression in first episode of psychosis baseline conditions and to proinflammatory nuclear factor nuclear factor kB activity in follow-up conditions, respectively.
Conclusions: Our results support the need for integrating cardiovascular healthcare very early after the first episode of psychosis.

Idioma: Inglés
DOI: 10.1093/ijnp/pyx110
Año: 2018
Publicado en: International Journal of Neuropsychopharmacology 21, 5 (2018), 410-422
ISSN: 1461-1457

Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Psiquiatría (Departamento de Medicina, Psiquiatría y Dermatología)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial.

Exportado de SIDERAL (2018-06-18-08:57:58)

Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Psiquiatría

 Registro creado el 2018-06-18, última modificación el 2018-06-18

Versión publicada:
Valore este documento:

Rate this document:
(Sin ninguna reseña)